Figure 3.
Observed changes in CA 15-3 levels in patients 3 months prior to secondary progression after experiencing clinical benefit with fulvestrant treatment (n = 28).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.